Tyra Biosciences, Inc. (NASDAQ:TYRA) Given Average Rating of “Buy” by Analysts

Tyra Biosciences, Inc. (NASDAQ:TYRA) has been given an average recommendation of “Buy” by the seven ratings firms that are currently covering the firm, MarketBeat Ratings reports. Six analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. The average 12-month price target among analysts that have issued a report on the stock in the last year is $31.8571.

Several equities research analysts have commented on the company. Oppenheimer reissued an “outperform” rating and issued a $36.00 target price on shares of Tyra Biosciences in a report on Wednesday, September 10th. Raymond James Financial assumed coverage on Tyra Biosciences in a report on Tuesday, September 2nd. They issued a “strong-buy” rating and a $35.00 target price on the stock. Wall Street Zen raised Tyra Biosciences from a “sell” rating to a “hold” rating in a report on Saturday, September 13th. Finally, HC Wainwright reissued a “buy” rating and issued a $30.00 target price on shares of Tyra Biosciences in a report on Friday, August 22nd.

Tyra Biosciences Stock Up 5.3%

Shares of TYRA stock opened at $12.79 on Friday. The stock has a market cap of $681.71 million, a price-to-earnings ratio of -7.19 and a beta of 1.10. The business’s fifty day moving average is $11.38 and its 200 day moving average is $10.30. Tyra Biosciences has a twelve month low of $6.42 and a twelve month high of $29.60.

Tyra Biosciences (NASDAQ:TYRA) last issued its quarterly earnings results on Thursday, August 14th. The company reported ($0.47) earnings per share for the quarter, topping the consensus estimate of ($0.53) by $0.06. Equities research analysts expect that Tyra Biosciences will post -1.57 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Tyra Biosciences

Several hedge funds have recently added to or reduced their stakes in TYRA. Commodore Capital LP lifted its holdings in shares of Tyra Biosciences by 226.3% during the second quarter. Commodore Capital LP now owns 3,100,000 shares of the company’s stock valued at $29,667,000 after purchasing an additional 2,150,000 shares in the last quarter. Vestal Point Capital LP lifted its holdings in shares of Tyra Biosciences by 190.9% during the first quarter. Vestal Point Capital LP now owns 2,879,829 shares of the company’s stock valued at $26,782,000 after purchasing an additional 1,889,829 shares in the last quarter. Sio Capital Management LLC lifted its holdings in shares of Tyra Biosciences by 94.5% during the second quarter. Sio Capital Management LLC now owns 810,274 shares of the company’s stock valued at $7,754,000 after purchasing an additional 393,657 shares in the last quarter. Balyasny Asset Management L.P. lifted its holdings in shares of Tyra Biosciences by 139.8% during the second quarter. Balyasny Asset Management L.P. now owns 583,386 shares of the company’s stock valued at $5,583,000 after purchasing an additional 340,142 shares in the last quarter. Finally, Millennium Management LLC lifted its holdings in shares of Tyra Biosciences by 2,900.2% during the fourth quarter. Millennium Management LLC now owns 315,141 shares of the company’s stock valued at $4,380,000 after purchasing an additional 304,637 shares in the last quarter. 84.14% of the stock is owned by institutional investors.

Tyra Biosciences Company Profile

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.